检索结果-南通市图书馆

Progress towards onchocerciasis elimination in the participating countries of the African Programme for Onchocerciasis Control: epidemiological evaluation results

引用

Infectious Diseases of Poverty 2016年第1期5卷 557-581页

作者： Afework H.Tekle honorath g.m.zouré mounkaila Noma michel Boussinesq Luc E.Coffeng Wilma A.Stolk Jan H.F.Remme African Programme for Onchocerciasis Control OuagadougouBurkina Faso Institut de Recherche pour le Développement(IRD) MontpellierFrance Department of Public Health Erasmus MCUniversity Medical Center RotterdamRotterdamThe Netherlands 120 rue des Campanules OrnexFrance

Background:The African Programme for Onchocerciasis Control(APOC)was created in 1995 to establish community-directed treatment with ivermectin(CDTi)in order to control onchocerciasis as a public health problem in 20 African countries that had 80%of the global disease *** research showed that CDTi may ultimately eliminate onchocerciasis infection,APOC was given in 2008 the additional objective to determine when and where treatment can be safely *** report the results of epidemiological evaluations undertaken from 2008 to 2014 to assess progress towards elimination in CDTi areas with≥6 years ***:Skin snip surveys were undertaken in samples of first-line villages to determine the prevalence of *** *** were two evaluation *** decline in prevalence was evaluated in phase *** and model-predicted prevalences were compared after correcting for endemicity level and treatment *** statistics and monte Carlo simulation were used to classify the decline in prevalence as faster than predicted,on track or *** the prevalence approached elimination levels,phase 1B was launched to determine if treatment could be safely *** sampling was extended to the whole CDTi *** data were analysed within a Bayesian framework to determine if stopping criteria(overall prevalencemaximum stratum prevalencem 639 villages in 54 areas were *** prevalence had fallen *** decline in prevalence was faster than predicted in 23 areas,on track in another 23 and delayed in eight *** phase 1B 108636 people in 392 villages were examined in 22 areas of which 13 met the epidemiological criteria for stopping ***,32 areas(25.4 million people)had reached or were close to elimination,18 areas(17.4 million)were on track but required more years treatment,and in eight areas(10.4 million)progress was unsatisfactory.

关键词： Onchocerciasis Ivermectin APOC Elimination Community-directed treatment ONCHOSIm

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

A practical approach for scaling up the alternative strategy for the elimination of lymphatic filariasis in Loa loa endemic countries-developing an action plan

引用

global Health Research and Policy 2017年第1期2卷 254-260页

作者： Louise A.Kelly-Hope michelle C.Stanton Honorat g.m.zouré Boniface E.Kinvi Alexei mikhailov Afework Tekle Jonathan D.King Department of Parasitology Liverpool School of Tropical MedicineLiverpoolUK African Programme for Onchocerciasis Control OuagadougouBurkina Faso Communicable Disease Unit World Health OrganizationRegional Office for AfricaBrazzavilleCongo Department of Control of Neglected Tropical Diseases World Health OrganizationGenevaSwitzerland

Background:Lymphatic filariasis(LF)is a vector-borne parasitic disease that is being targeted for elimination through mass drug administration(mDA).The co-distribution of Loa loa in Central Africa poses a significant barrier to the expansion of the mDA due to risk of severe adverse events(SAEs)associated with the drug ivermectin that is routinely *** LF programmes are yet to significantly scale up in co-endemic areas and need a practical approach to make preliminary decisions based on the mapping status and potential treatment ***:We reviewed relevant data available to WHO and in the literature for *** endemic countries to develop a simple method to support the scale-up of mDA to eliminate ***:A basic model for national LF programmes to work from at the administrative or implementation unit(IU)level has been developed for LF–*** co-endemic *** model includes five practical steps,which comprise the development of a national filarial database and a simple classification system to help determine the mapping status and most appropriate treatment *** are colour-coded and linked to a general decision tree,which is also ***:This IU-level model is simple to follow and will help LF elimination programmes develop an action plan and scale up the implementation of alternative treatment strategies in *** co-endemic *** model could be further developed to incorporate the additional complexity of IUs where an intervention is required to eliminate onchocerciasis,particularly in hypo-endemic areas where ivermectin has not been used.

关键词： routine elimination action

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

State of the HIV, Hepatitis B and C Virus Pandemic from 2003 to 2022 in Burkina Faso: Evolution of Prevalence Trends and Strategic Recommendations to Achieve the WHO’s goal for Their Eradication by 2030

引用

Advances in Infectious Diseases 2024年第3期14卷 628-643页

作者： Abdou Azaque zouré Christelle Nadembega Djénéba Ouermi Abdoul Karim Ouattara Lassina Traoré Adama Tiemtoré Olivier Sawadogo Théodora m. Zohoncon Florencia W. Djigma Jacques Simpore Cerba-Labiogene group Centre de Recherche Biomolculaire Pietro Annigoni (CERBA) Ouagadougou Burkina Faso Laboratoire de Biologie molculaire et de gntique (LABIOgENE) Universit Joseph KI-ZERBO Ouagadougou Burkina Faso Institute for Research in Health Sciences (IRSS/CNRST) Ouaga Burkina Faso Department of Biomedical Hpital Saint Camille de Ouagadougou (HOSCO) Ouagadougou Burkina Faso Department of Biology Universit Norbert Zongo/Centre Universitaire de Manga Koudougou Burkina Faso Department of mathematic Universit de Ouahigouya Ouahigouya Burkina Faso Faculty of medicine University Saint Thomas dAquin (USTA) Ouagadougou Burkina Faso

Background: The World Health Organization (WHO) has set a goal to eradicate or at least significantly reduce the prevalence the human immunodeficiency virus (HIV), hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) by 2030. The main objective was to provide an evolving overview of the prevalence of HIV, HBV and HCV infection between 2003 and 2022 in Burkina Faso. methods: It was a retrospective cross-sectional study based on data from 2003 to 2022. The data were collected using information available in the databases of the HOSCO and CERBA laboratories and included all individuals who underwent HIV and/or HBV and/or HCV testing. Data analysis was performed using SPSS version 20.0, EpiInfo 7, and R version 4.1.0. Results were considered statistically significant if p Results: The study recorded 7432 samples and the mean age of the subjects was 27.98 ± 8.50 years. During this period, the respective prevalence of HIV, HBV, and HCV were 4.66% (346/7432), 8.77% (582/6636) and 5.54% (322/5816). However, from 2003 to 2022, there was a significant decrease (P y=−1.75x+12.59;y=−0.24x+10.01and y=−0.11x+6.02, with “y” corresponding to prevalence and “x” to the years. Conclusion: Burkina Faso needs to rigorously apply prevention and control strategies recommended by the WHO by 2030.

关键词： HIV Viral Hepatitis B and C WHO’s 2030 goal Burkina Faso

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

ST of Streptococcus pneumonia Circulating in Burkina Faso before the Introduction of PCV-13, 2013

引用

Advances in microbiology 2023年第5期13卷 237-248页

作者： Kambiré Dinanibè Tamboura mamadou Ouédraogo Oumarou Tondé Issa Ouédraogo W. H. gautier Sanou mahamoudou zouré Abdou Azaque Compaoré Rebeca Sagna Tani Soubeiga R. S. Théophile Zida Sylvie Aké Flavien Abdoul-Salam Ouédraogo Sangaré Lassana méda Isaïe Kouanda Séni Ouédraogo-Traoré Rasmata Centre Hospitalier Universitaire Pédiatrique Charles De gaulle Ouagadougou Burkina Faso Institut de Recherche en Sciences de la Santé Ouagadougou Burkina Faso Davycas International Ouagadougou Burkina Faso Centre Hospitalier Universitaire Yalgado Ouédraogo Ouagadougou Burkina Faso Centre Hospitalier Universitaire Sanon Sourô Bobo-Dioulasso Burkina Faso Direction générale de la Santé Publique Ouagadougou Burkina Faso

Introduction: Burkina Faso experiences regular cases of Streptococcus pneumoniae meningitis. As part of the strategy to reduce cases of meningitis, the 13-valent pneumococcal conjugate vaccine (PCV-13) has been introduced in the Expanded Programme on Immunisation (EPI). Despite these efforts, there are some cases of pneumococcal meningitis including both vaccine and non-vaccine serotypes. The objective of this study was to describe the pneumococcal sequence types (ST) circulating in Burkina Faso before the introduction of the 13-valent pneumococcal conjugate vaccine (PCV-13). methods: It was a descriptive cross-sectional study that took place from 27th October 2013 to 7th January 2014. S. pneumoniae strains were collected in Burkina Faso and multi Locus Sequence Typing (mLST) was performed at the Pneumococcal Laboratory at the Centers for Disease Control and Prevention (CDC) in the USA (United States of America). mLST consists of 4 steps: amplification, purification, sequencing and interpretative reading of the results. The amplification used 7 primers consisting of sequences of aroe, gdh, gki, recP, spi, xpt, ddl genes. Results: Of 37 strains tested, 10 serotypes were identified. Serotype 1 was prevalent in 48.7% (18/37) followed by serotype 25F in 10.8% (4/37). Serotypes 5 and 12F/12A/12B/44/46 were 8.1% (3/37) each. Serotype 1 contained 5 STs including ST303 24.3% (9/37), ST217 8.1% (3/37) and ST618 8.1% (3/37);followed by serotype 25F with ST105 10.8% (4/37), serotype 5 with ST289 8.1% (3/37) and serogroup 12F/12A/12B/44/46 with ST 989 8.1% (3/37). Conclusion: Pneumococci are characterised by their great variability both in number of serotypes and in ST within the same serotype. Thus, 10 serotypes have been identified. Also, within serotype 1, 5 different STs have been described. These data indicate the complexity of the pneumococcus which is strongly involved in purulent bacterial meningitis at national level. This requires continuous surveillance of pneumococc

关键词： Streptococcus pneumoniae Burkina Faso PCV-13 Sequence Types

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

meningitis Outbreak Caused by Neisseria meningitidis Serogroup C ST 10217 in 2019 in Diapaga, Burkina Faso

引用

Advances in Infectious Diseases 2023年第1期13卷 66-76页

作者： Kambiré Dinanibè Tondé Issa Ouédraogo W. H. gautier Sanou mahamoudou Ouédraogo L. S. L. Wilfrid Savadogo mahamoudou Tamboura mamadou Zongo moumouni Ouédraogo Oumarou zouré Abdou Azaque Compaoré Rebeca Sagna Tani Zida Sylvie Soubeiga R. S. Théophile Aké Flavien Sangaré Lassana méda Isaïe Kouanda Séni Ouédraogo-Traoré Rasmata Centre Hospitalier Pédiatrique Universitaire Charles De Gaulle Ouagadougou Burkina Faso Institut de Recherche en Sciences de la Santé Ouagadougou Burkina Faso Direction de la protection de la Santé de la Population Ouagadougou Burkina Faso Centre Hospitalier Universitaire Yalgado Ouédraogo Ouagadougou Burkina Faso Davycas International Ouagadougou Burkina Faso Direction générale de la Santé Publique Ouagadougou Burkina Faso

Introduction: meningitis caused by Neisseria meningitidis constitutes a burden for the countries in the meningitis belt of sub-Saharan in general and particularly for Burkina Faso. In 2019 the Diapaga health district experienced a meningitis epidemic due to N. meningitidis serogroup C. methods: This is a cross-sectional study with a descriptive aim in the health district of Diapaga where all cases of meningitis were included in this work. Rapid diagnostic tests (RDTs), culture as well as real-time PCR were used for the biological analysis of cerebral spinal fluid (CSF) samples. Results: Of 155 CSF samples analysed, 42% (65/155) were tested positve. Of them, N. meningitidis C accounted for 83% of all positive cases. Likewise, all thirteen (13) NmC strains were susceptible to oxacillin, ceftriaxone, penicillin and chloramphenicol. All strains of NmC belonged to the sequence type (ST) 10 217 and to the clonal complex (CC) 10 217. These CCs belonged to the same variant PorA type: P1.21-15.16;FetA type: F1-7;PorB type: 3-463. Conclusion: Burkina Faso had known an epidemic of meningitis caused by NmC in 2019 in the health district of Diapaga. This outbreak was contained in time due to the performance of the epidemiological surveillance system which made it possible to investigate on time and introduce the vaccine against the pathogen NmC.

关键词： meningitis Neisseria meningitidis VS Diapaga Burkina Faso

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：